This book aims at providing an overview and in depth analysis of recent developments in stem cell research and therapy. It is composed of recently published review articles that went through peer-review process. Stem cells are the building blocks of the body. They can develop into any of the cells that make up our bodies. Stem cells hold a great deal of hope for the treatment of a broad range of diseases and injuries, spanning from cancers, diabetes, genetic diseases, graft-versus-host disease, eye, heart and liver diseases, inflammatory and autoimmune disorders, to neurological diseases and injuries. These include neurodegenerative diseases, such as Alzheimers and Parkinsons diseases, cerebral strokes, and traumatic brain and spinal cord injuries. Therefore, Stem cell research is as important for understanding of the physio- and pathology of the body, as for development and therapy, including the nervous system. Volume V provides an overview and in depth analysis of recent developments in the front of patent applications filed and clinical trials initiated in the field of stem cells, in the aim of introducing stem cell research into therapy.
Introduction:: Therapeutic neuronal stem cells:: patents at the forefront; Adult neurogenesis and pharmacology in Alzheimers disease and depression; Adult neurogenesis in the pathogenesis of Alzheimers disease; Therapeutic potential of adult neural stem cells; Human neural progenitor and stem cells; Cryopreservation of early post-mitotic neuronal cells in culture; Adult neural stem cells for the treatment of neuroinflammation; Adult periodontal-derived neural progenitor and stem cells; Magnetic resonance imaging for monitoring neurogenesis in the adult hippocampus; Apigenin and related compounds stimulate adult neurogenesis; Nootropic agents stimulate neurogenesis; Fourteen compounds and their derivatives for the treatment of diseases and injuries characterised by reduced neurogenesis and neurodegeneration; Brevetoxin derivative compounds for stimulating neuronal growth; OTI-010 Osiris Therapeutics/JCR Pharmaceuticals; ADA-transduced hematopoietic stem cell therapy for ADA-SCID; Index.
Komentarze (0)
Chwilowo nie możesz polubić tej opinii
Zgłoś komentarz
Czy jesteś pewien, że chcesz zgłosić ten komentarz?
Zgłoszenie wysłane
Twój komentarz został wysłany i będzie widoczny po zatwierdzeniu przez moderatora.